1. GlaxoSmithKline reported a 17% increase in pharma sales in the first quarter of 2017, mainly driven by Triumeq, Tivicay, and Relvar/Breo Ellipta. It also said that its earnings may be affected this year if a generic competitor for its respiratory treatment Advair is introduced in the market. (WaPo)
2. Eli Lilly plans to meet with the FDA in the next 60 days to discuss the application for its experimental rheumatoid arthritis drug baricitinib. The drug, which the FDA declined to approve earlier this month, is already approved in Europe. (Reuters)
3. The FDA issued 14 warning letters and four online advisory letters to U.S. companies illegally selling more than 65 products that claim to treat cancer. Most of them are sold online without FDA approval.
4. AstraZeneca delayed the completion of a clinical study testing its experimental immunotherapy drugs, durvalumab and tremelimumab, in lung cancer patients to November 15. (Reuters)
5. Vending machines in China are now selling HIV testing kits on university campuses, as part of an experimental program to reach students reluctant to visit clinics due to the stigma associated with HIV. (NPR)